INAB — IN8BIO, INC.

—
Nasdaq · Health Care · Biotechnology · CIK 1740279 ·
Last close
$0.82
Market Cap
$8.86M
52W High
$2.73
52W Low
$0.72
ADV30
205,510
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -4,721,000 -4,592,000 18,695,000 13,973,000 4,521,000
Jun 2026 0 — -4,935,000 -4,781,000 21,745,000 17,956,000 3,382,000
Mar 2026 0 — -5,266,000 -5,090,000 26,265,000 21,941,000 3,484,000
Dec 2025 0 — -5,033,000 -4,942,000 32,282,000 27,092,000 4,724,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-14,355,000
Investing CF
$-242,000
Financing CF
$19,232,000
CapEx
$-242,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.60
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-150,967,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-19,201,000
Pretax Income TTM
$-18,667,000
Interest Exp TTM
—
Analysts
3

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -19,861,000 -19,440,000 32,282,000 4,724,000 27,558,000 -12,712,000
Dec 2024 0 -29,599,000 -30,437,000 20,944,000 6,466,000 14,478,000 -24,149,000
Dec 2023 0 -30,007,000 -30,007,000 33,709,000 8,772,000 24,937,000 -23,340,000
Dec 2022 0 -28,521,000 -28,521,000 33,039,000 10,307,000 22,732,000 -24,121,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$534,000
NetIncome TTM
$-18,667,000
OpCashFlow TTM
—
Assets (Latest)
$21,745,000
Forward EPS
$-0.95

Peers — same industry

TickerNameMarket CapLastDaily %
INTS INTENSITY THERAPEUTICS, INC. $8.81M $2.67 —
TCRX TScan Therapeutics, Inc. $9.59M $0.15 —
BCLI BRAINSTORM CELL THERAPEUTICS INC. $9.72M $0.88 —
CUBT Curative Biotechnology Inc $7.56M $0.85 —
ALGS Aligos Therapeutics, Inc. $7.40M $1.36 —

News headlines (Yahoo Finance, 1h cache)

IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
2026-11-16 13:00 · Yahoo
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-11-06 21:01 · Yahoo
IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-05 21:01 · Yahoo
IN8bio to Present at Sidoti Small-Cap Virtual Conference
2026-09-22 20:00 · Yahoo
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
2026-09-09 12:00 · Yahoo
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-06 20:01 · Yahoo
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
2026-07-09 12:00 · Yahoo
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-07 20:30 · Yahoo
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
2026-05-06 12:00 · Yahoo
IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma
2026-05-14 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.